CUHK World-First Study Identifies Genetic Markers of  Young-Onset Type 2 Diabetes in Chinese Population, Develops Novel Risk Score for Early Diagnosis and Prevention
(From right) Professor Ronald Ma Ching-wan, Professor Juliana Chan Chung-ngor, Dr Fan Baoqi, Professor Andrea Luk On-yan, Dr Cadmon Lim King-poo

CUHK World-First Study Identifies Genetic Markers of Young-Onset Type 2 Diabetes in Chinese Population, Develops Novel Risk Score for Early Diagnosis and Prevention

The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has conducted the world’s first and largest genetic association study of age at diagnosis of type 2 diabetes in a Chinese population. The study identified three genetic regions associated with younger disease onset, impaired insulin-producing beta-cell function, and poorer blood glucose control. Based on the distinct genetic markers, the multidisciplinary team pioneered an innovative Age-at-Diabetes-Diagnosis Genetic Risk Score (ADD-GRS) capable of early, low-cost identification of high-risk Chinese individuals, paving the way for more precise prevention and personalised intervention. The findings have been published in the leading international journal Genome Medicine.

Title: A genome-wide association study and genetic risk score for age at diabetes diagnosis support beta-cell dysfunction in young-onset diabetes in Chinese

Authors: Baoqi Fan, Claudia H. T. Tam, Andrea O. Y. Luk, Eric S. H. Lau, Cadmon K. P. Lim, Mai Shi, Raymond Wan, Stephanie H. M. Cheung, Yingnan Fan, Alex C. W. Ng, Hongjiang Wu, Aimin Yang, Juliana N. M. Lui, Heung-Man Lee, Elaine Chow, Alice P. S. Kong, Risa Ozaki, Chun-Kwun O, Gechang Yu, Chuiguo Huang, Maggie H. T. Wang, Samuel Y. S. Wong, Eric K. P. Lee, Alfred Hu, Dandan Yan, Weiping Jia, Ka-Fai Lee, Shing-Chung Siu, Grace Hui, Chiu-Chi Tsang, Kam-Piu Lau, Jenny Y. Y. Leung, Elaine Y. N. Cheung, Man Wo Tsang, Grace Kam, Ip-Tim Lau, June K. Y. Li, Vincent T. F. Yeung, Emmy Lau, Stanley Lo, Samuel Fung, Yuk Lun Cheng, Chun-Chung Chow, Xiaodan Fan, Ting-Fung Chan, Kevin Y. L. Yip, Si Lok, Weichuan Yu, Stephen K. W. Tsui, Hui-Yao Lan, Cheuk-Chun Szeto, Nelson L. S. Tang, Brian Tomlinson, Yu Huang, Wing-Yee So, Ronald C. W. Ma, Juliana C. N. Chan.
 

Diabetes affects one in every nine adults worldwide and was the 10th leading cause of death in Hong Kong in 2025.1 Type 2 diabetes, the most common form of diabetes, occurs when the body cannot produce or use insulin effectively, leading to high blood glucose. Insulin, the only hormone that lowers blood glucose levels, is exclusively produced and released by the beta-cells in the pancreas.

In Asia, young-onset diabetes, diagnosed before the age of 40, accounts for one in five type 2 diabetes cases, a prevalence twice that observed in European populations. Compared to later-onset diabetes, it is associated with faster beta-cell function decline and longer high blood glucose exposure. The prolonged condition damages blood vessels and multiple organs, raising the premature death risk by four- to ninefold compared with peers without diabetes. Diabetes arises from complex interactions among genetic, life-course and environmental factors. However, most global genetic studies have historically focused on older populations of European descent.

Addressing an Asian health epidemic with discovery of risk genetic loci

Led by Professor Juliana Chan Chung-ngor, Founding Director of the Hong Kong Institute of Diabetes and Obesity and Professor in the Department of Medicine and Therapeutics at CU Medicine, the research team has addressed the major healthcare disparity by decoding the genetic architecture of young-onset diabetes in Chinese populations.

Using genetic data from more than 22,000 Chinese individuals in Hong Kong with young- or late-onset diabetes, the team conducted a genome-wide association study (GWAS) – a comprehensive scan of a person’s DNA coding – to identify genetic variants associated with a younger age at diagnosis of diabetes and related traits.

The researchers identified three genetic regions – KCNQ1, PAX4 and CDKAL1 – that are associated with young-onset diabetes in Chinese populations. Within or near each region, the researchers identified an independent genetic variant distinctly associated with the disease. These three variants were found to be common in the target population, with frequencies ranging from 19% to 70%, and each may account for an estimated 4.6% to 14.2% of young-onset diabetes cases.

Dr Fan Baoqi, Research Associate and data analyst in the Department of Medicine and Therapeutics at CU Medicine, explained:  “These fairly common DNA codes increase a person’s chances of developing diabetes at a young age in the presence of other risk factors, such as smoking, obesity and psychosocial stress. While we cannot alter a person’s DNA codes, identifying these high-risk individuals for targeted intervention on modifiable factors such as body weight will have significant public health implications. For those who have already developed young-onset diabetes, the presence of these variants indicates compromised beta-cell function, calling for more intensified treatment to improve control of blood glucose and other risk factors to protect the beta-cells and prevent premature organ damage.”

Uncovering distinct risk pathways related to beta-cell dysfunction

The top variants identified in the study demonstrated inter-ethnic differences in prevalence and confirmed the key role of beta-cell dysfunction in Chinese patients. Key findings of this paper are as follows:

  • Asian-specific prevalence: The lead variant near CDKAL1 is over twice as common in Asians as in Europeans, while the Asian-specific PAX4 variant and common KCNQ1 risk variant are key genetic markers of young-onset diabetes in Chinese populations.
  • Uncaptured genetic risk: The variants at PAX4 and KCNQ1 contribute to risks that are not captured by European or South Indian genetic risk models for the age at diabetes diagnosis. In the diabetes cohort, the leading PAX4 variant is associated with poorer blood glucose control and reduced insulin production.
  • Beta-cell dysfunction link: Compared with British Pakistani and Bangladeshi populations, where young-onset diabetes is associated with both insulin deficiency and fat storage abnormalities, the condition among Chinese is more strongly linked to genetic variants affecting beta-cells.

Professor Ronald Ma Ching-wan, SH Ho Professor of Diabetes and Head of Division (Academic Affairs) of the Division of Endocrinology and Diabetes, Department of Medicine and Therapeutics, CU Medicine, said: “Over the past three decades, CU Medicine researchers have been among the leading contributors from Asia to global diabetes genetics research, identifying Asian-relevant genetic risk factors. In this analysis, we also found a suggestive variant associated with a young age at diagnosis that is also associated with kidney disease in European patients with type 1 diabetes. Further research is needed to explore potential shared risk pathways which may explain why Asians have a high tendency of developing young-onset diabetes and kidney disease, with both conditions being growing global health concerns.”

A scalable, cost-effective new tool for earlier and more precise detection and intervention

Building on these findings, the CU Medicine research team has developed ADD-GRS. A higher ADD-GRS is associated with poorer glycaemic control, lower insulin production, and a younger age at diagnosis. People whose GRS ranks among the highest 5% to 20% could be diagnosed with diabetes 6 to 12 months earlier than average, with other genetic and non-genetic risk factors potentially leading to an even younger age at diagnosis.

The ADD-GRS scale may offer an Asian-relevant, low-cost and potentially more precise tool for genetic risk screening. Unlike complex large-scale genetic risk scores developed from multi-ancestry populations consisting of thousands of genetic markers, the ADD-GRS is based on three key genetic markers that are particularly relevant to Chinese populations, making genetic testing and risk stratification more cost-effective than genome-wide testing. Application of the ADD-GRS could enable early detection and prevention by identifying at-risk young people for a prioritised early oral glucose tolerance test (OGTT), the gold standard test for diagnosing diabetes and prediabetes.

Professor Andrea Luk On-yan, Professor (Clinical) in the Department of Medicine and Therapeutics and Medical Director (Non-oncology) of the Phase 1 Clinical Trial Centre at CU Medicine, remarked: “Our modelling showed that an individual diagnosed with diabetes at age 33 may accumulate around 100 days of hospitalisation by age 70. Even with optimal control of cardiometabolic risk factors such as blood pressure, blood cholesterol, blood glucose and body weight, hospitalisation risk drops by only about 30%. In contrast, delaying the onset of diabetes until the age of 50 to 60 has the potential to substantially reduce the burden of recurrent hospitalisation.”

Professor Chan remarked: “Diabetes is like a loaded gun that only fires when the trigger of risk factors is pulled. Each person has a unique risk profile shaped by a complex mix of genetic and lifestyle factors, with family history, age, and obesity among the most important contributors. As a result, each person has a unique threshold for developing diabetes, which affects when the disease appears. By combining genetic variants with other risk factors, we can develop personalised risk scores to identify people most likely to develop young-onset diabetes with better precision. This allows us to offer targeted testing, regular monitoring and earlier intervention, empowering young people to make informed decisions and lead longer, healthier lives.”

[1] According to the number of registered deaths by leading cause of death by sex and age group, 2025, presented by the Centre for Health Protection, Department of Health, The Government of the HKSAR

You can also read:

Celebrating the Successful Unveiling of the Guangzhou Laboratory–CUHK Joint Laboratory and the Guangdong–Hong Kong Joint Laboratory for Testing and Evaluation of Biological Products and Medical Devices

CUHK